Sylvain Ladoire
0000-0002-0331-9194
Publication & Citation Trends
Publications
0 total
Abstract P5-10-10: PELICAN-IPC 2015-016/Oncodistinct-003: a randomized phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer
Cited by 0
Semantic Scholar
Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption
Cited by 9
Semantic Scholar
Abstract PS11-02: [18F]fluoroestradiol (FES) PET/CT to guide 2nd line treatment decision in patients with ER-positive HER2-negative advanced breast cancer (ABC) progressing on 1st line aromatase inhibitor and CDK4/6 inhibitor: early results of the ESTROTIMP trial
Cited by 1
Semantic Scholar
Abstract PO5-11-04: Sexuality and fertility profiles, Health-Related Quality of Life and other living conditions of young breast cancer survivors in France: a national cross-sectional study by the French Network of Cancer Registries (FRANCIM)
Cited by 0
Semantic Scholar
Abstract 1187: Sensitization to chemo-immunotherapy by targeting TGF-β in preclinical triple negative breast cancer models
Cited by 0
Semantic Scholar
HER2-Low Luminal Breast Carcinoma Is Not a Homogenous Clinicopathological and Molecular Entity OA
Cited by 2
Semantic Scholar
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
Cited by 40
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(110)
Bladder and Urothelial Cancer Treatments
(54)
Breast Cancer Treatment Studies
(50)
Renal cell carcinoma treatment
(43)
Immunotherapy and Immune Responses
(39)
Affiliations
Semmelweis University
University of Geneva
Conservatoire National des Arts et Métiers
Brigham and Women's Hospital
Centre National de la Recherche Scientifique